Sydney Lupkin
Sydney Lupkin is the pharmaceuticals correspondent for NPR.
She was most recently a correspondent at Kaiser Health News, where she covered drug prices and specialized in data reporting for its enterprise team. She's reported on how tainted drugs can reach consumers, how companies take advantage of rare disease drug rules and how FDA-approved generics often don't make it to market. She's also tracked pharmaceutical dollars to patient advocacy groups and members of Congress. Her work has won the National Press Club's Joan M. Friedenberg Online Journalism Award, the National Institute for Health Care Management's Digital Media Award and a health reporting award from the Society for Advancing Business Editing and Writing.
Lupkin graduated from Boston University. She's also worked for ABC News, VICE News, MedPage Today and The Bay Citizen. Her internship and part-time work includes stints at ProPublica, The Boston Globe, The Boston Herald, The New England Center for Investigative Reporting and WCVB.
-
The Food and Drug Administration rejected Moderna's new flu shot. This raises questions about what it means for the future of vaccine development.
-
Under Trump administration deals to lower drug prices, pharmaceutical companies are offering some of their drugs at discounted prices through a new website called TrumpRx.gov. -
Gene therapy drugs have the potential to cure some diseases, but some have a price tag of over a million dollars. Who gets access to them and who doesn't?
-
Every January, pharmaceutical companies increase the prices of hundreds of drugs. This year there's a disconnect between the deals with the Trump administration on some drug prices versus others.
-
The Wegovy pill approved in December arrived at pharmacies nationwide on Monday. Patients now have a new way to take the weight loss medication.
-
There's a new pill and new ways to pay for the weight-loss drugs known as GLP-1s.
-
Mail theft can happen around the holidays, but sometimes, instead of getting a new iPad, the thief swipes a mail order medicine. Here's what to do about it. -
Pill versions of the obesity drugs now taken only as injections are on the way. We look at the science behind the pills and if they might be more affordable and accessible than the shots.
-
The Trump administration struck deals with pharmaceutical companies Novo Nordisk and Eli Lilly to lower prices and copays for type 2 diabetes and obesity drugs --- but not everyone will qualify.
-
Medicare beneficiaries will soon be able to get obesity and Type 2 diabetes drugs for a $50 copay. But there are some limitations.
